Nervous System Diseases: Clinical Trials

5,925 trials for Nervous System Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3513 completed, 651 terminated, 577 unknown, 548 recruiting. 5925 Phase 3, 1031 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35925Completed 3513, Terminated 651, Unknown 577, Recruiting 548, Active not recruiting 222, Not yet recruiting 189, Withdrawn 176, Enrolling by invitation 31, Suspended 18
Phase 21031Completed 513, Unknown 161, Terminated 115, Recruiting 105, Not yet recruiting 48, Active not recruiting 39, Withdrawn 39, Suspended 6, Enrolling by invitation 5

Follow Nervous System Diseases: new trials by email Literature Review of Nervous System Diseases trials Research Report on Nervous System Diseases

Trials (filtered) newest first · largest first

All 5,925 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial
testosterone cypionate, finasteride, placebo injection - Spinal Cord Injury, Spinal Cord Injuries
Phase 2 / Phase 3Not yet recruitingVA Office of Research and Development3002027-10-012026-08-04
Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis
Acetyl Salicylic Acid (ASA), Placebo - Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS)
Phase 3Not yet recruitingCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal1202027-10-012026-10-30
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
GV1001 Placebo, GV1001 1.12mg - Moderate to Severe Alzheimer's Disease
Phase 3Not yet recruitingSamsung Pharmaceutical Co., Ltd.7502027-07-012026-06-10
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
NTI164, Placebo - RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome
Phase 2 / Phase 3Not yet recruitingFenix Innovation Group402027-07-012026-09-09
Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
Tricaprilin, Placebo - Alzheimer Disease
Phase 3Not yet recruitingCerecin5352027-07-012026-10-30
Valproic AcId for Traumatic BRAin INjury Trial
Valproic Acid (VPA), Standard of care treatment + normal saline - Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury
Phase 2 / Phase 3Not yet recruitingNorthwestern University4322027-05-012026-11-05
Intranasal Stem Cells to Treat Perinatal Brain Injury to Combat Cerebral Palsy
MSC, marrow, Placebo - Perinatal Arterial Ischemic Stroke, Perinatal Asphyxia
Phase 2 / Phase 3Not yet recruitingUMC Utrecht1622027-04-012026-09-21
Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours
Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg) - Acute Ischemic Stroke, Large Vessel Occlusion
Phase 3Not yet recruitingFujian Medical University Union Hospital12662027-04-012026-11-03
A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple Sclerosis
Frexalimab, Frexalimab Placebo, Teriflunomide - Multiple Sclerosis
Phase 3Not yet recruitingSanofi25002027-02-152026-11-12
Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
LUM-201 - Growth Hormone Deficiency (GHD)
Phase 3Not yet recruitingLumos Pharma1502027-02-012026-07-08
Corticosteroid Lumbar Epidural Analgesia for Radicular Pain 2
SP-102, Placebo, Dexamethasone Sodium Phosphate 10 MG/ML - Lumbosacral Radicular Pain
Phase 3Not yet recruitingSemnur Pharmaceuticals, Inc.7552027-02-012026-09-09
Optimizing Care for Cryptococcal Antigenemia: Evaluation of Short Course Fluconazole and ART Timing Among CrAg+ Persons With Low Titers
Immediate ART Initiation, Delayed ART Initiation, 10-Week Fluconazole - Cryptococcal Antigenemia, HIV-1-infection
Phase 3Not yet recruitingUniversity of Minnesota5052027-01-052026-09-03
Dexmedetomidine for Invasive Ventilation In the NEOnate
Dexmedetomidine Injectable Solution, Glucose 5% Injectable Solution - Invasive Ventilation, Infant Pain
Phase 2 / Phase 3Not yet recruitingCentre Hospitalier Intercommunal Creteil2462027-01-012026-08-26
Safety of F14 Following Total Knee Replacement
F14 (sustained release celecoxib) - Analgesia
Phase 2 / Phase 3SuspendedArthritis Innovation Corporation1002027-01-012026-06-05
A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)
ONO-2808, Placebo - Multiple System Atrophy, Parkinson Variant
Phase 3Not yet recruitingOno Pharmaceutical Co., Ltd.4862027-01-012026-09-17
Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant
Intravenous tenecteplase (TNK), Placebo - Acute Ischemic Stroke
Phase 3Not yet recruitingHackensack Meridian Health6602027-01-012026-06-02
A Randomized Trial of Botulinum Toxin A vs Strabismus Surgery for Esotropia >10 to ≤30PD
Botulinum toxin A, bilateral medial rectus recession - Esotropia
Phase 3Not yet recruitingJaeb Center for Health Research2442027-01-012026-04-06
A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
Arbaclofen, Placebo - Spasticity
Phase 3Not yet recruitingRVL Pharmaceuticals, Inc.4422027-01-012025-12-03
CiLostAzol for pReventIon of Recurrent sTroke in Africa
Cilostazol 100 mg - Stroke
Phase 3Not yet recruitingNorthern California Institute of Research and Education11002027-01-012026-11-12
A Multicenter, Open-label, Randomized, Non-inferiority Clinical Trial With Blinded Endpoint Assessment of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
Tirofiban Injection - Acute Ischemic Stroke
Phase 2 / Phase 3Not yet recruitingXinqiao Hospital of Chongqing11922026-12-192026-11-06

Showing 20 of 5925. Sign in to see all of them.

Narrower conditions

Stroke (411)  ·  Alzheimer Disease (346)  ·  Ischemic Stroke (328)  ·  Parkinson Disease (289)  ·  Epilepsy (262)  ·  Agnosia (254)  ·  Migraine Disorders (243)  ·  Multiple Sclerosis (239)  ·  Pain (193)  ·  Sleep Initiation and Maintenance Disorders (169)  ·  Seizures (163)  ·  Brain Neoplasms (149)  ·  Dementia (138)  ·  Poliomyelitis (101)  ·  Sleep Apnea, Obstructive (99)

Broader conditions

Central Nervous System Diseases (3353)  ·  Brain Diseases (2894)  ·  Pathological Conditions, Signs and Symptoms (2283)  ·  Signs and Symptoms (1776)  ·  Neurologic Manifestations (1711)  ·  Neurodegenerative Diseases (1047)  ·  Mental Disorders (1042)  ·  Cardiovascular Diseases (1002)  ·  Vascular Diseases (999)  ·  Neuromuscular Diseases (946)  ·  Cerebrovascular Disorders (864)  ·  Pathologic Processes (764)  ·  Neurobehavioral Manifestations (686)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (646)

Interventions

Sodium Chloride (102)  ·  Saline Solution (97)  ·  Pregabalin (82)  ·  Aspirin (79)  ·  Botulinum Toxins, Type A (70)  ·  Dexmedetomidine (64)  ·  Levetiracetam (54)  ·  Radiotherapy (48)  ·  Tenecteplase (47)  ·  Clopidogrel (46)  ·  Topiramate (46)  ·  Dexamethasone (43)  ·  Ketamine (39)  ·  Gabapentin (38)  ·  Lacosamide (36)

Sponsors

Pfizer (103)  ·  GlaxoSmithKline (98)  ·  Novartis Pharmaceuticals (93)  ·  Assistance Publique - Hôpitaux de Paris (84)  ·  Eli Lilly and Company (66)  ·  Sanofi (63)  ·  UCB Pharma (63)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (61)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (58)  ·  Biogen (56)  ·  Sanofi Pasteur, a Sanofi Company (52)  ·  Jazz Pharmaceuticals (47)  ·  Hoffmann-La Roche (45)  ·  Beijing Tiantan Hospital (42)  ·  Merck Sharp & Dohme LLC (37)

Countries

United States (2598)  ·  Canada (1039)  ·  France (1000)  ·  Germany (978)  ·  United Kingdom (854)  ·  Spain (851)  ·  Italy (791)  ·  Poland (648)  ·  Australia (613)  ·  China (604)  ·  Belgium (499)  ·  Netherlands (488)  ·  Japan (470)  ·  Czechia (415)  ·  Russia (363)

Results publications

PMID 31867054, PMID 39498781, PMID 18190818, PMID 12807523, PMID 40603145, PMID 20451898, PMID 11914403, PMID 2375765, PMID 26899665, PMID 33825230, PMID 36700520, PMID 22108357, PMID 34218211, PMID 33461041, PMID 34022170, PMID 34487721, PMID 34515113, PMID 35224730, PMID 37870112, PMID 38557959, PMID 39800465, PMID 39982105, PMID 8984084, PMID 16731270, PMID 21899409, PMID 25475413, PMID 25823975, PMID 26120369, PMID 26402769, PMID 26694975, PMID 27448285, PMID 27611736, PMID 27733070, PMID 30936738, PMID 31284771, PMID 31926466, PMID 33023488, PMID 33189083, PMID 33263359, PMID 33395098, PMID 34383289, PMID 35285519, PMID 35305920, PMID 35978286, PMID 36449262, PMID 37059702, PMID 37460385, PMID 37652990, PMID 37796657, PMID 40258203

NIH funding

2023 (72), 2015 (63), 2014 (59), 2016 (56), 2018 (55), 2019 (52), 2025 (50), 2017 (46), 2009 (40), 2008 (36), 2004 (27), 2005 (15), U10EY011751 (15), U10CA180868 (6), U10CA180886 (6)